Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide

Rapalink-1 Targets Glioblastoma Stem Cells and Acts Synergistically with Tumor Treating Fields to Reduce Resistance against Temozolomide

Glioblastoma (GBM) is a lethal disease with limited clinical treatment options available. Recently, a new inhibitor targeting the prominent cancer signaling pathway mTOR was discovered (Rapalink-1), but its therapeutic potential on stem cell populations of GBM is unknown. We applied a collection of...

Full description

Bibliographic Details
Main Authors: Andres Vargas-Toscano, Ann-Christin Nickel, Guanzhang Li, Marcel Alexander Kamp, Sajjad Muhammad, Gabriel Leprivier, Ellen Fritsche, Roger A. Barker, Michael Sabel, Hans-Jakob Steiger, Wei Zhang, Daniel Hänggi, Ulf Dietrich Kahlert
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
glioblastoma
rapalink-1
tumor treating fields
EMT
therapy resistance
human stem cell in vitro platform
Online Access:https://www.mdpi.com/2072-6694/12/12/3859

Internet

https://www.mdpi.com/2072-6694/12/12/3859

Similar Items